What did Goldman Sachs do in the latest ARWR analyst rating update?

On **February 9, 2026**, Goldman Sachs **maintained a Neutral** rating on ARWR. The note did not include a new price target and the stock moved **-2.13% ($-1.36)** on the news. See the StreetInsider synopsis for details [source](https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Reiterates

Does the Neutral rating change the investment case for Arrowhead Pharmaceuticals?

A Neutral rating signals a hold stance; it does not remove the long-term thesis but suggests limited near-term upside from this analyst. Investors should weigh commercial progress, upcoming readouts, and financing before adjusting positions.

Were any new ARWR price targets issued with this rating?

No. Goldman Sachs reiterated its Neutral rating on **February 9, 2026** without publishing a new ARWR price target. Investors should watch for future analyst notes for updated targets.

How does Meyka suggest using the ARWR analyst rating?

Meyka advises using the ARWR analyst rating as one input among many. Meyka AI rates ARWR **A**, and that grade combines benchmark comparison, sector strength, growth metrics, and analyst views to guide monitoring and position sizing.

Analyst Ratings

Goldman Sachs Maintains Neutral on ARWR Arrowhead Pharmaceuticals Feb 2026

ByHuzaifa Zahoor February 10, 2026February 10, 2026

Goldman Sachs maintained a Neutral rating on Arrowhead Pharmaceuticals, Inc. (ARWR) on February 9, 2026, the firm reiterated its view without a new price target. The ARWR analyst rating update arrived after modest intraday weakness, with the stock down 2.13% ($-1.36) versus its prior close. This action leaves the near-term analyst consensus unchanged and signals that Goldman Sachs is waiting for clearer commercial and clinical traction before moving to a more positive call. Market cap stands at $8,760,413,806 and investors should weigh this rating against the company’s recent pipeline and financing developments.